These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122 [TBL] [Abstract][Full Text] [Related]
4. Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion. Meyer JC; Shah GK; Blinder KJ; Waheed NK; Reichel E; Stalmans P; Singer M; Tewari A Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):209-16. PubMed ID: 25707046 [TBL] [Abstract][Full Text] [Related]
5. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou? Kim JE JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332 [No Abstract] [Full Text] [Related]
6. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. Varma R; Haller JA; Kaiser PK JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086 [TBL] [Abstract][Full Text] [Related]
7. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ; Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816 [TBL] [Abstract][Full Text] [Related]
8. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495 [TBL] [Abstract][Full Text] [Related]
9. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology. Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990 [TBL] [Abstract][Full Text] [Related]
10. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Kaiser PK; Kampik A; Kuppermann BD; Girach A; Rizzo S; Sergott RC Retina; 2015 Jun; 35(6):1111-27. PubMed ID: 25635577 [TBL] [Abstract][Full Text] [Related]
11. Treatment of vitreomacular traction with intravitreal ocriplasmin preceded by anterior chamber paracentesis: case reports. Rizzo S; Bacherini D; Abbruzzese G; Giuntoli M; Virgili G Eur J Ophthalmol; 2016 Aug; 26(5):e134-7. PubMed ID: 26951534 [TBL] [Abstract][Full Text] [Related]
12. Injectable drug may help avoid eye surgery in patients with vitreomacular adhesion. Morrow T Manag Care; 2013 Jan; 22(1):49-50. PubMed ID: 23373143 [No Abstract] [Full Text] [Related]
13. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA; Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630 [TBL] [Abstract][Full Text] [Related]
14. Ocriplasmin use in a selected case with preserved visual acuity. Rossi S; Orrico A; Melillo P; Testa F; Simonelli F; Della Corte M BMC Ophthalmol; 2015 Oct; 15():146. PubMed ID: 26511080 [TBL] [Abstract][Full Text] [Related]
15. Initial experience with ocriplasmin in the treatment of vitreomacular traction. Garcia JM; Isaac DL; Ávila M Arq Bras Oftalmol; 2016 Apr; 79(2):85-7. PubMed ID: 27224069 [TBL] [Abstract][Full Text] [Related]
16. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection. Abou Ltaif S; Herbert L BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463 [TBL] [Abstract][Full Text] [Related]
17. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin. Luttrull JK Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240 [TBL] [Abstract][Full Text] [Related]
18. EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS. Bormann C; Apitzsch BC; Habermann A; Hammer U; Hammer T Retin Cases Brief Rep; 2020; 14(4):377-380. PubMed ID: 29621042 [TBL] [Abstract][Full Text] [Related]
19. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection. Katz RS Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167 [TBL] [Abstract][Full Text] [Related]
20. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release. Modi YS; Singh RP Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]